In order to help expedite the review process, manufacturers or sponsors are expected to summarize drug submission data related to quality, or safety and efficacy, using the following WordPerfect® or MS Word templates, as appropriate, with drug submissions filed to the Biologics and Genetic Therapies Directorate.
In this topic:
Additional Resources:
Reconsideration of Final Decisions - Request for reconsideration